RESEARCH ARTICLE

Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling

In Ah Park¹, Seong-Hye Hwang¹,², In Hye Song¹, Sun-Hee Heo¹,², Young-Ae Kim¹,², Won Seon Bang¹,², Hye Seon Park¹,², Miseon Lee¹, Gyungyub Gong¹, Hee Jin Lee¹ *

¹ Departments of Pathology, Asan Medical Center, Seoul, Korea, ² Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

☯ These authors contributed equally to this work.
* backilla@gmail.com

Abstract

Tumor-infiltrating lymphocytes (TILs) have been known for their strong prognostic and predictive significance in triple-negative breast cancer (TNBC). Several mechanisms for TIL influx in TNBC have been elucidated. Major histocompatibility complex class II (MHC-II) is an essential component of the adaptive immune system and is generally restricted to the surface of antigen-presenting cells. However, it has been reported that interferon-gamma signaling may induce MHC-II in almost all cell types, including those derived from cancer. We aimed to examine the relationship between MHC-II expression in tumor cells and the amount of TILs in 681 patients with TNBC. Further, the prognostic significance of MHC-II and the association of MHC-II with a couple of molecules involved in the interferon signaling pathway were investigated using immunohistochemical staining. Higher MHC-II expression in tumor cells was associated with the absence of lymphovascular invasion (p = 0.042); larger amounts of TILs (p < 0.001); frequent formations of tertiary lymphoid structures (p < 0.001); higher expression of myxovirus resistance gene A, one of the main mediators of the interferon signaling pathway (p < 0.001); and higher expression of double-stranded RNA-activated protein kinase, which can be induced by interferons (p = 0.008). Moreover, tumors that showed high MHC class I expression and any positivity for MHC-II had larger amounts of CD4- and CD8-positive T lymphocytes (p < 0.001). Positive MHC-II expression in tumor cells was associated with better disease-free survival in patients who had lymph node metastasis (p = 0.009). In conclusion, MHC-II expression in tumor cells was closely associated with an increase in TIL number and interferon signaling in TNBC. Further studies are warranted to improve our understanding regarding TIL influx, as well as patients’ responses to immunotherapy.
Introduction

Triple-negative breast cancer (TNBC) is a clinical subtype of invasive tumors that have low or no expression of hormone receptors, such as estrogen receptor (ER) and progesterone receptor (PR), and no overexpression of human epidermal growth factor receptor 2 (HER2). Patients with TNBC, an aggressive type of cancer, are not candidates for ER- or HER2-targeted therapy. Most patients receive adjuvant or neoadjuvant chemotherapy with or without local radiotherapy [1].

In our previous study, we revealed that the expression of major histocompatibility complex (MHC) class I in TNBC is associated with tumor-infiltrating lymphocytes (TILs) and interferon (IFN) signaling in tumor cells [2]. We also reported that one of the main mediators of IFN signaling, myxovirus resistance gene A (MxA), is associated with TILs and is a prognostic factor for TNBC [3]. The presence of TILs can be assessed through histologic examination, immunohistochemistry, and genomic methodologies. The concluding remarks from many TIL studies on breast cancer show that the immune response of patients has a positive effect on therapy response, progression-free survival, and overall survival, especially in TNBC [4–9]. So far, the importance of TILs is usually emphasized by the roles of CD8-positive T cells. However, CD4-positive T cells also have an important role in the antitumor response in both mice and humans. After immunization with cancer cells or specific peptides, tumor suppression depends on a functional CD4-positive T cell effector compartment [10]. Helper T cells have been shown to directly mobilize effector cytotoxic T lymphocytes to virus-infected tissues [11]. Such interaction might be crucial in some cancers.

Antigen presentation by MHC-II, also known as human leukocyte antigen (HLA)–II (HLA-DR, -DP, and -DQ) in humans with co-chaperones HLA-DM and the invariant chain (Ii), is essential for antitumor immunity and the development of adaptive immune responses [12–15]. Generally, MHC-II expression is known to be restricted to professional antigen presenting cells, such as dendritic cells, macrophages, and B cells, but is inducible through IFN-γ signaling in almost all cell types, including those derived from cancer [16, 17]. Recently, the capability of CD4-positive T cells to directly kill MHC-II-expressing target cells in an MHC-II–CD4-restricted manner, independent of B, NK, or other T cells in the host, has been reported [18–20].

Although HLA-II expression in breast cancer has been previously reported, most of the studies have analyzed only a small number of breast cancer tissues or conducted whole transcriptome analysis using RNA sequencing, which might have represented HLA-II expression in immune cells rather than cancer cells [21–24]. In the current study, we evaluated the expression of MHC-I, MHC-II (HLA-DR, -DP, and -DQ), and IFN-Associated molecules in tumor cells; TIL percentage; and the number of CD4- and CD8-expressing cells in a large number of TNBC cases. This study elucidates the role of HLA-II expression in TNBC tumor cells.

Materials and methods

Patients and tissue specimens

A total of 681 preoperative chemo- and radiotherapy naïve-patients with TNBC who underwent surgery for primary breast cancer from 2004 to 2010 at the Asan Medical Center, Seoul, Korea, were included in this study. All patients underwent adjuvant systemic treatment, while 550 patients (80.8%) were treated with adjuvant radiotherapy. Of the 681 patients, 471 (69.2%) were treated with four cycles of adjuvant anthracycline and cyclophosphamide (AC) (adriamycin 60 mg/m² and cyclophosphamide 600 mg/m²). The remaining 210 patients were treated with four cycles of AC followed by either four cycles of paclitaxel (175 mg/m²) or four cycles of
docetaxel (75 mg/m²). Those who had lymph node metastasis were treated with AC and taxane, whereas those who did not were treated with AC. We obtained the patients’ clinicopathological information from their medical records and surgical pathology reports. The Institutional Review Board of Asan Medical Center approved this study for the exemption from informed consent after de-identification of information.

The definition of TNBC in terms of the expression of biomarkers, including ER, PR, and HER2, and HER2 gene amplification recognized by fluorescence in situ hybridization or silver in situ hybridization was the same as previously described [25].

**Histological evaluation**

Hematoxylin-and-eosin (H&E)-stained slides were reviewed by two pathologists (H.J.L. and G.G.). The slides were then histopathologically analyzed for TILs (defined as the percentage of stroma of invasive carcinoma infiltrated by lymphocytes in 10% increments; if less than 10% of the stroma was infiltrated by TILs, 1% or 5% was used; all available full sections were evaluated) [26], the amount of inflammatory cells at the border of the tumor’s invasive area (according to Klintrup criteria; score 0, no inflammatory cells at the invasive border; score 1, mild and patchy increase of inflammatory cells; score 2, increased inflammatory reaction forming a band-like infiltrate at the invasive border; score 3, prominent inflammatory cells forming a cup-like zone at the invasive border) [27], the amount of tertiary lymphoid structures (TLSs) in the adjacent area of the invasive and in situ components of the tumor (none, no TLS formation in the area adjacent to the tumor; little, TLSs occupying an area of less than 10% of the circumference of the tumor; moderate, 10% to 50%; abundant, over 50%) [25], histologic subtype and grade, tumor size, pathological tumor stage (pT), pathological lymph node stage (pN), and lymphovascular invasion. TLSs were confirmed when lymphoid aggregates showed vessels having high endothelial venule-like features (plump and cuboidal endothelium) with or without germinal centers. Histological type was defined based on the 2012 WHO classification criteria, while histological grade was assessed using the modified Bloom–Richardson classification [28].

**Clinicopathological characteristics of the study population**

The median age of the patients at the time of diagnosis was 47.4 years (range, 23 to 76 years). Tumor sizes of invasive portion ranged from 0.3 to 9 cm (median, 2.5 cm). There were 299 cases of pT1, 356 cases of pT2, 25 cases of pT3, and 1 case of pT4. In terms of pathological lymph node stage (pN), 472, 121, 46, and 42 cases were pN0, pN1, pN2, and pN3, respectively.

**Tissue microarray construction and immunohistochemical evaluation**

Formalin-fixed, paraffin-embedded tissue samples were arrayed using a tissue-arraying instrument, as previously described [29]. Each sample was arrayed in three 1-mm-diameter cores to minimize tissue loss and overcome tumor heterogeneity. Tissue microarray sections were stained using an automatic immunohistochemical staining device (Benchmark XT; Ventana Medical Systems, Tucson, AZ). Antibodies for MHC-I (HLA-ABC; 1:1600; ab70328; EMR8-5; Abcam, Cambridge, UK), MHC-II (HLA-DR, -DP, and -DQ; 1:1000; CR3/43; Santa Cruz Biotechnology, Santa Cruz, CA), MxA (1:1000; ab95926; Abcam), double-stranded RNA-activated protein kinase (PKR, 1:400; ab32052; Abcam), CD4 (1:4; Ventana Medical Systems), and CD8 (1:200; DAKO, Glostrup, Denmark) were used. All protein expression except CD4 and CD8 was evaluated using a four-value intensity score (0, 1, 2, and 3) in tumor cells. The percentage of membranous and/or cytoplasmic expression was also evaluated. The “immunoreactive score” was derived from the product of intensity and positively stained tumor cell percentage.
Immunoreactive scores were dichotomized by the mean value of the expression of each protein, while tumors having immunoreactive scores of zero were designated as “no” expression (Fig 1). The immunostained tissue microarray slides for CD4 and CD8 were scanned using a digital microscope scanner (Pannoramic 250 FLASH, 3DHISTECH Ltd., Budapest, Hungary). The number of CD4- and CD8-positive cells in tissue microarray cores was determined using the NuclearQuant module of the Pannoramic Viewer 1.15.2 (3DHISTECH Ltd). Representative images of immunohistochemical staining for CD4 and CD8 are shown in S1 Fig.

Statistical analysis

All statistical analyses were performed using SPSS statistical software (version 18; SPSS, Chicago, IL). The Kruskal–Wallis test, Mann–Whitney test, linear-by-linear association test, log-rank test, and Cox proportional hazards regression model were used as appropriate. All tests were two-sided, and statistical significance was set at 5%.

Results

Higher MHC-II expression in tumor cells is associated with larger amounts of tumoral and peritumoral lymphocytes, and molecules involved in interferon signaling pathway

The expression level of MHC-II in tumor cells was dichotomized by its mean value using immunohistochemical staining. We divided the tumors into three groups, those with no (479 cases, 70.3%), low (86 cases, 12.6%), and high (116 cases, 17.0%) expression of MHC-II molecules, to compare the clinicopathological variables according to the expression level (Table 1). Tumors with higher MHC-II expression were shown to have lower lymphovascular invasion

Fig 1. Representative image of triple-negative breast cancer (A) hematoxylin-and-eosin-stained slide and the three degrees of major histocompatibility complex (MHC) class II expression in tumor cells. (B) No MHC-II expression and (C) lower and (D) higher expression than the mean value of the immunoreactive score, which was generated as the product of intensity and percentage of positively stained cells.

https://doi.org/10.1371/journal.pone.0182786.g001
Table 1. Comparison of clinicopathological variables according to MHC-II expression in tumor cells.

|                          | MHC-II expression |          |          |       |
|--------------------------|-------------------|----------|----------|-------|
|                          | No (n = 479)      | Low* (n = 86) | High* (n = 116) | p value |
| **Histological grade**   |                   |          |          |       |
| 1                        | 0                 | 0        | 0 (0.0%) | 0.041 |
| 2                        | 21 (18.1%)        | 14 (16.3%)| 126 (26.3%)|       |
| 3                        | 95 (81.9%)        | 72 (83.7%)| 353 (73.7%)|       |
| **Pathologic T stage**   |                   |          |          | 0.074 |
| 1                        | 213 (44.5%)       | 45 (52.3%)| 41 (35.3%) |       |
| 2                        | 243 (50.7%)       | 40 (46.5%)| 73 (62.9%) |       |
| 3                        | 22 (4.6%)         | 1 (1.2%)  | 2 (1.7%)  |       |
| 4                        | 1 (0.2%)          | 0        | 0        |       |
| **Lymph node metastasis**|                   |          |          | 0.726 |
| Negative                 | 332 (69.3%)       | 57 (66.3%)| 83 (71.6%) |       |
| Positive                 | 147 (30.7%)       | 29 (33.7%)| 33 (28.4%) |       |
| **Lymphovascular invasion**|                 |          |          | 0.042 |
| Negative                 | 355 (74.1%)       | 69 (80.2%)| 98 (84.5%) |       |
| Positive                 | 124 (25.9%)       | 17 (19.8%)| 18 (15.5%) |       |
| **TILs (%)**             |                   |          |          | <0.001|
| ≤10                      | 144 (30.1%)       | 13 (15.1%)| 8 (6.9%)  |       |
| 20–30                    | 118 (24.6%)       | 16 (18.6%)| 20 (17.2%)|       |
| 40–60                    | 95 (19.8%)        | 19 (22.1%)| 34 (29.3%)|       |
| >60                      | 122 (25.5%)       | 38 (44.2%)| 54 (46.6%)|       |
| **Peritumoral lymphocytes (Klintrup criteria)** | | | | <0.001|
| 0                        | 40 (8.4%)         | 2 (2.3%)  | 0 (0.0%)  |       |
| 1                        | 194 (40.5%)       | 21 (24.4%)| 21 (18.1%)|       |
| 2                        | 184 (38.4%)       | 45 (52.3%)| 57 (49.1%)|       |
| 3                        | 61 (12.7%)        | 18 (20.9%)| 38 (32.8%)|       |
| **TLS adjacent to the invasive area** | | | | <0.001|
| No                      | 50 (10.4%)        | 4 (4.7%)  | 1 (0.9%)  |       |
| Mild                     | 85 (17.7%)        | 12 (14.1%)| 12 (10.3%)|       |
| Moderate                 | 173 (36.1%)       | 36 (41.9%)| 42 (36.2%)|       |
| Severe                   | 171 (35.7%)       | 34 (39.5%)| 61 (52.6%)|       |
| **MHC class I expression** |                  |          |          | <0.001|
| Low                      | 271 (58.0%)       | 33 (38.4%)| 11 (9.5%) |       |
| High                     | 196 (42.0%)       | 53 (61.6%)| 105 (90.5%)|      |
| **PD-L1 expression**     |                   |          |          | <0.001|
| Negative                 | 440 (96.7%)       | 74 (87.1%)| 83 (71.6%)|       |
| Positive (any)           | 15 (3.3%)         | 11 (12.9%)| 33 (28.4%)|       |
| **MxA expression**       |                   |          |          | <0.001|
| Low                      | 321 (67.9%)       | 48 (55.8%)| 50 (43.1%)|       |
| High                     | 152 (32.1%)       | 38 (44.2%)| 66 (56.9%)|       |
| **PKR expression**       |                   |          |          | 0.008 |
| Low                      | 256 (54.6%)       | 37 (43.0%)| 47 (40.5%)|       |
| High                     | 213 (45.4%)       | 49 (57.0%)| 69 (59.5%)|       |

*The expression of MHC-II molecules was dichotomized into low and high groups using the mean of the immunoreactive score, 27.2; MxA, myxovirus resistance A; PKR, double-stranded RNA-activated protein kinase; TILs, tumor infiltrating lymphocytes; TLS, tertiary lymphoid structure.

https://doi.org/10.1371/journal.pone.0182786.t001
(p = 0.042), larger amounts of TILs (p < 0.001), higher Klinstrup criteria scores (p < 0.001), and larger amounts of TLSs adjacent to the invasive tumor area (p < 0.001). Programmed death-ligand 1 (PD-L1) expression in any tumor cell was significantly associated with higher expression levels of MHC-II (p < 0.001). Higher expression of MxA, one of the main mediators of the IFN signaling pathway, was correlated with higher MHC-II expression (p < 0.001). Expression of PKR, which has numerous physiological and pathological functions during cellular stress and can be induced by IFN signaling, also showed a positive correlation with MHC-II expression (p = 0.008). These results suggest that MHC-II expression in tumor cells is associated with not only tumoral and peritumoral lymphocytic infiltration but also the IFN signaling pathway.

In addition, we analyzed the association between clinicopathological variables and MHC-II expression in tumor cells after dividing the patients into two groups according to lymph node metastasis (S1 Table). Same tendency was observed in both groups.

**Tumors showing high MHC-I expression and positivity for MHC-II have larger amounts of lymphocytes**

Antigen presentation by MHC-I and -II in tumor cells is critical for effective antitumor activity of TILs. We divided the patients into four groups by combining MHC-I and -II expression levels. MHC-I well known to be expressed on the all types of nucleated cells was dichotomized by the mean value of its expression. Whereas, in terms of MHC-II which is normally found only on professional antigen-presenting cells, we divided patients into two groups, one of which included patients who showed total negativity for MHC-II (“no” in Fig 2) and the other of which included patients who had tumors with positivity for MHC-II regardless of percentage and intensity (“any positive” in Fig 2). A total of 271 patients (39.7%) had an MHC-I expression level that was lower than the mean value and no MHC-II expression, while 44 patients (6.4%) showed lower MHC-I expression and positivity for MHC-II in tumor cells. Moreover, 196 (28.7%) patients showed higher MHC-I expression and no MHC-II expression, whereas 158 patients (23.1%) had higher MHC-I expression and positivity for MHC-II. Average amounts of CD4- and CD8-positive lymphocytes were evaluated and compared among these four groups using the Kruskal–Wallis test. We also executed all six possible comparisons for each subset of lymphocytes as post analyses using the Mann–Whitney test. As shown in Fig 2, tumors that showed high MHC-I expression and positivity for MHC-II had significantly larger amounts of CD4- and CD8-positive lymphocytes than all the other groups. However, tumors with either high MHC-I expression or positivity for MHC-II revealed to have more lymphocytes than those with low MHC-I expression and no MHC-II expression.

**Tumor cells with MHC-II expression are associated with better prognosis in patients with lymph node metastasis**

Next, we conducted survival analyses using clinicopathological factors that could affect the patients’ clinical outcomes as variables (Table 2). Higher pT, presence of lymph node metastasis and lymphovascular invasion, fewer amounts of TILs, lesser formation of TLSs adjacent to invasive area, and lower expression of MxA were significantly negatively associated with disease-free survival (all p ≤ 0.002). Subgroup analysis showed that these negative prognostic factors, except MxA expression, remained statistically significant for patients with lymph node metastasis, whereas pT, lymphovascular invasion, and MxA expression were effective prognostic factors in patients without lymph node metastasis. Expression levels of MHC-I, PD-L1, and PKR in tumor cells did not show a significant association with clinical outcomes.
Fig 2. The amount of CD4-positive (A) and CD8-positive (B) lymphocytes according to protein expression of MHC-I and -II in tumor cells. The patients were divided into four groups by combining MHC-I and -II expression levels. MHC-I was dichotomized by the mean value of its expression. In case of MHC-II, 'no' designates the cases with total negativity for MHC-II, and the others who have tumors with positivity for MHC-II regardless of percentage and intensity are designated as ‘any positive’. (*p < 0.05; **p < 0.01; ***p < 0.001).

https://doi.org/10.1371/journal.pone.0182786.g002
As shown in Fig 3, patients having tumors with any positive expression of MHC-II tended to have better survival rates, though the relationship was not statistically significant ($p = 0.130$). When we compared Kaplan-Meyer survival curves of the four subgroups in combination of MHC-I (low/high) and MHC-II (no/positive), tumors with no MHC-II expression tended to have worse prognosis regardless of MHC-I status (data not shown), although this result was also not statistically significant. However, in patients who had lymph node metastasis, any MHC-II expression in tumor cells was significantly associated with better disease-free survival ($p = 0.009$). After multivariate analysis including MHC-II expression, pT stage, lymphovascular invasion, level of TILs, and TLSs, MHC-II expression was not an independent prognostic factor. Remnant variables which have been found to be independent prognostic factors in total patients as well as lymph node-positive and -negative subgroups are described in S2 Table.

### Discussion

The present study showed that 29.7% of TNBC cells expressed MHC-II. A previous study that performed immunohistochemical analysis with anti-CD74 (HLA class II histocompatibility antigen gamma chain) and anti-HLA-DPB1 in TNBC tumor specimens [22] revealed that all five examined specimens had CD74 protein expression in tumor cells. The staining was cytoplasmic, membranous, or both, with 5% to 90% of tumor cells showing immune reactivity that was weak to moderate in intensity. HLA-DPB1 protein expression was noted in two of five
TNBC tumors, with weak-to-moderate cytoplasmic and membranous staining in 20% and 40% of tumor cells, respectively. The expression of HLA-DR and HLA-DQ from breast cancer biopsies was also analyzed in 52 invasive ductal carcinomas using immunohistochemistry [23]. Moreover, 86.5% of cancers showed high levels of HLA-DQ, whereas 69.2% showed low levels of HLA-DR expression. In another study, HLA-DR expression was examined using immunohistochemical methods in five medullary breast carcinomas, six atypical medullary carcinomas, and 20 invasive ductal carcinomas [24]. Expression was most dominant in medullary carcinomas, followed by atypical medullary carcinomas and invasive duct carcinomas with and without lymphocytic infiltrates. The mean intensity and percentage of HLA-DR tumor immunostaining were significantly higher in medullary carcinomas than in the other three.

Fig 3. Kaplan–Meier survival curves according to MHC-II expression in tumor cells. (A) All patients, (B) patients with lymph node metastasis, and (C) patients without lymph node metastasis.

https://doi.org/10.1371/journal.pone.0182786.g003
tumor groups. These results are concordant with those of the present study, given the significant correlation between MHC-II expression in tumor cells and the level of TILs in TNBCs.

We found prognostic significance of MHC-II expression in TNBCs with lymph node metastasis, although it was not an independent prognostic factor. These results may be explained by the significant correlation between MHC-II expression in tumor cells and TIL level, which is a strong prognostic factor for patients with TNBC. However, prognostic significance of MHC-II expression has also been shown in patients with melanoma receiving anti-programmed cell death protein 1 (PD-1) therapy and those with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [30, 31]. These findings suggest that increased MHC-II expression (and in turn increased antigen presentation) in tumor cells facilitates better antitumor response in the tumor microenvironment.

Current evidence has suggested that CD8-positive cytotoxic lymphocytes rely on CD4-positive T cells and can moderate the destruction of tumor cells [32–36]. Therefore, antigenic epitope presentation of both MHC-I and -II (MHC-I/II) induces high affinity T cells that respond to the MHC-I/II epitopes [37]. It has also been reported that naive tumor-specific CD4-positive T cells differentiate in vivo and eradicate established melanoma, tumor-responsive CD4-positive T cells improve cytotoxic activity and obliterate large established melanoma after transferring into lymphopenic hosts, and MHC-II-restricted cytotoxic T lymphocytes are generated by mature CD4-positive T helper cells [18–20]. Recently, effectiveness of neoantigen-derived cancer vaccines in two studies with melanoma patients has been described [38, 39]. Both studies showed dominant CD4-positive T cell responses to neo-epitopes. Therefore, MHC-II expression in tumor cells and its close association with CD4-positive T cells in our study suggests the possible cytotoxic activity of CD4-positive T cells on MHC-II expression in TNBC cells.

In the present study, we found a significant positive correlation between PD-L1 and MHC-II expression in TNBC. Recently, the safety and antitumor activity of the PD-1 inhibitor was assessed in a phase Ib trial involving patients with advanced TNBC [40]. Johnson et al. showed that HLA-DR positivity in tumor cells is related to a therapeutic response, as well as the amount of tumor infiltrated CD4- and CD8-positive T cells in anti-PD-1-treated patients with melanoma [41]. They also found that MHC-II-positive melanoma cell lines demonstrate signatures of “PD-1 signaling,” “allograft rejection,” and “T-cell receptor signaling,” among others using pathway analysis. Therefore, they suggested that MHC-II-positive tumors can be identified through immunohistochemistry using commercially available antibodies for MHC-II to improve anti-PD-1 patient selection.

A limitation of our study includes the heterogeneous expression of MHC-II. Given our use of tissue microarray to assess MHC-II expression in tumor cells, we cannot exclude the possibility that MHC-II-expressing tumor cells exist in other parts of the cancer tissue. Further studies exploring the role of MHC-II expression in tumor cells are warranted to discover effective ways of improving patients’ immune responses to cancer.

Supporting information
S1 Fig. Representative images of immunohistochemical staining for (A&B) CD4 and (C&D) CD8. The numbers of CD4- and CD8-positive cells in tissue microarray cores were substantially different among the cases, which were determined using half-automatic program. (PDF)

S1 Table. Comparison of clinicopathological variables according to MHC-II expression in tumor cells and lymph node metastasis. (DOCX)
S2 Table. Multivariate analyses of clinicopathological variables affecting disease-free survival.

Author Contributions

Conceptualization: Hee Jin Lee.

Data curation: In Ah Park, Seong-Hye Hwang, In Hye Song, Sun-Hee Heo, Hye Seon Park, Miseon Lee.

Formal analysis: In Ah Park.

Funding acquisition: In Ah Park, Hee Jin Lee.

Investigation: Seong-Hye Hwang.

Methodology: In Ah Park.

Project administration: Won Seon Bang.

Resources: Gyungyub Gong, Hee Jin Lee.

Software: In Ah Park.

Supervision: Gyungyub Gong.

Validation: Hee Jin Lee.

Visualization: In Ah Park.

Writing – original draft: In Ah Park, Seong-Hye Hwang.

Writing – review & editing: Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee.

References

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429–34. https://doi.org/10.1158/1078-0432.CCR-06-3045 PMID: 17671126.

2. Lee HJ, Song IH, Park IA, Heo SH, Kim YA, Ahn JH, et al. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget. 2016; 7(21):30119–32. https://doi.org/10.18632/oncotarget.8798 PMID: 27121061; PubMed Central PMCID: PMCPMC5058668.

3. Kim YA, Lee HJ, Heo SH, Park HS, Park SY, Bang W, et al. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. Breast cancer research and treatment. 2016; 156(3):597–606. Epub 2016/04/15. https://doi.org/10.1007/s10549-016-3786-z PMID: 27075916.

4. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(27):2959–66. Epub 2014/07/30. https://doi.org/10.1200/JCO.2013.55.0491 PMID: 25071121; PubMed Central PMCID: PMCPmc4162494.

5. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28(1):105–13. https://doi.org/10.1200/JCO.2009.23.7370 PMID: 19917869.

6. Iglesias MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(14):3818–29. Epub 2014/06/12. https://doi.org/10.1158/1078-0432.ccr-13-3368 PMID: 24916698; PubMed Central PMCID: PMCPmc4102637.
MHC-II expression in triple negative breast cancer

7. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast cancer research: BCR. 2011; 13(6):R126. Epub 2011/12/14. https://doi.org/10.1186/bcr3072 PMID: 22151962; PubMed Central PMCID: PMC326568.

8. Loi S. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014; 32(27):2935–40. https://doi.org/10.1200/JCO.2014.56.7677 PMID: 25071115.

9. Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J. Role of inflammatory infiltrates in triple negative breast cancer. Journal of clinical pathology. 2015; 68(7):506–10. https://doi.org/10.1136/jclinpath-2015-209444 PMID: 25750267.

10. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005; 22(3):371–83. Epub 2005/03/23. https://doi.org/10.1016/j.immuni.2005.02.003 PMID: 15780993.

11. Nakashini Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature. 2009; 462(7272):510–3. Epub 2009/11/10. https://doi.org/10.1038/ nature08511 PMID: 19896495; PubMed Central PMCID: PMC2789415.

12. Accolla RS, Frangione V, De Lerma Barbaro A, Mortara L. New strategies of mammmary cancer vaccination. The breast journal. 2010; 16 Suppl 1:S42–4. Epub 2010/11/10. https://doi.org/10.1111/j.1524-4741.2010.01003.x PMID: 21050309.

13. Accolla RS, Tosi G. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines. Journal of translational medicine. 2012; 10:154. Epub 2012/08/02. https://doi.org/10.1186/1479-5876-10-154 PMID: 22849661; PubMed Central PMCID: PMCPmc3478985.

14. Armstrong TD, Clements VK, Ostrand-Rosenberg S. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. Journal of immunology (Baltim ore, Md: 1950). 1998; 160(2):661–6. Epub 1998/04/29. PMID: 9551900.

15. Meazza R, Comes A, Oreno AM, Ferrini S, Accolla RS. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. European journal of immunology. 2003; 33(5):1183–92. Epub 2003/05/06. https://doi.org/10.1002/eji.200323712 PMID: 12731043.

16. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 1984; 81(15):4917–21. Epub 1984/08/01. PMID: 6431411; PubMed Central PMCID: PMCPmc391603.

17. Jabbrane-Ferrat N, Faille A, Loiseau P, Poirier O, Charron D, Calvo F. Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines. International journal of cancer. 1990; 45(6):1169–76. Epub 1990/06/15. PMID: 2121525.

18. Mucida D, Husain MM, Murri S, van Wijk F, Shinnakasu R, Naoe Y, et al. Transcriptional reprogramming of mature CD4(-) helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nature immunology. 2013; 14(3):281–9. Epub 2013/01/22. https://doi.org/10.1038/ni.2523 PMID: 23334788; PubMed Central PMCID: PMCPmc3581083.

19. Quezada SA, Simpson TR, Peggs KS, Merghouth T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of experimental medicine. 2010; 207(3):637–50. Epub 2010/02/17. https://doi.org/10.1084/jem.20091918 PMID: 20156971; PubMed Central PMCID: PMCPmc2839156.

20. Xie Y, Akpinari A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. The Journal of experimental medicine. 2010; 207 (3):651–67. Epub 2010/02/17. https://doi.org/10.1084/jem.20091921 PMID: 20156973; PubMed Central PMCID: PMCPmc2839147.

21. Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. International immunology. 2006; 18(11):1591–602. https://doi.org/10.1093/intimm/dxl092 PMID: 16987935.

22. Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, et al. Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer immunology research. 2016; 4(5):390–9. https://doi.org/10.1158/2326-6066.CIR-15-0243 PMID: 26980599; PubMed Central PMCID: PMC4878913.

23. da Silva GB, Silva TG, Duarte RA, Neto NL, Carrara HH, Donadi EA, et al. Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer. International journal of breast cancer. 2013; 2013:250435. https://doi.org/10.1155/2013/250435 PMID: 24369393; PubMed Central PMCID: PMC3864140.
24. Feinmesser M, Suikes A, Morgenstem S, Suikes J, Stern S, Okon E. HLA-DR and beta 2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. Journal of clinical pathology. 2000; 53(4):286–91. https://doi.org/10.1136/jcp.53.4.286 PMID: 10823125; PubMed Central PMCID: PMC1731169.

25. Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, et al. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. Journal of clinical pathology. 2016; 69(5):422–30. https://doi.org/10.1136/jclinpath-2015-203089 PMID: 26475777.

26. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruner G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer; recommendations by an International TILs Working Group 2014. Ann Oncol. 2015; 26(2):259–71. Epub 2014/09/13. https://doi.org/10.1093/annonc/mdu450 PMID: 26214542.

27. Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012; 107(5):864–73. https://doi.org/10.1038/bjc.2012.347 PMID: 22978371; PubMed Central PMCID: PMC3426752.

28. Lakhani SR, Schnitt SJ, Tan PH, van de Vijver MJ, editor. WHO Classification of Tumours of the Breast. 4th ed. Lyon: International Agency for Research on Cancer; 2012.

29. Lee HJ, Seo AN, Park SY, Kim JY, Park JY, Yu JH, et al. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Annals of surgical oncology. 2014; 21(5):1561–6. Epub 2014/01/05. https://doi.org/10.1292/jj0144-013-3456-x PMID: 24385208.

30. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalinski SR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/ PD-L1 therapy. Nature communications. 2016; 7:10582. https://doi.org/10.1038/ncomms10582 PMID: 26823833; PubMed Central PMCID: PMC4740184.

31. Brown PJ, Wong KK, Felce SL, Lyne L, Spearman H, Soilleux EJ, et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia. 2016; 30(3):605–16. https://doi.org/10.1038/leu.2015.299 PMID: 26500140; PubMed Central PMCID: PMC4777777.

32. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. The Journal of experimental medicine. 1998; 188(12):2357–68. Epub 1998/12/22. PMID: 985522; PubMed Central PMCID: PMCPmc2212434.

33. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(15):8633–8. Epub 1999/07/21. PMID: 10411127; PubMed Central PMCID: PMC17568.

34. Qin Z, Blankenstein T. CD4+ T cell—mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000; 12(6):677–86. Epub 2000/07/14. PMID: 10894167.

35. Tanaka Y, Koido S, Xia J, Ohana M, Liu C, Cote GM, et al. Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion. Journal of immunology (Baltimore, Md: 1950). 2004; 172(12):7848–58. Epub 2004/06/10. PMID: 15187169.

36. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. The Journal of experimental medicine. 1999; 189(5):753–6. Epub 1999/03/02. PMID: 10049938; PubMed Central PMCID: PMCPmc2192956.

37. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. The Journal of experimental medicine. 2000; 192(11):1535–44. Epub 2000/12/06. PMID: 11104796; PubMed Central PMCID: PMCPmc2193101.

38. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662):217–21. https://doi.org/10.1038/nature22991 PMID: 28678778.

39. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547(7662):222–6. https://doi.org/10.1038/nature23003 PMID: 28678784.

40. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2016; 34(21):2460–7. Epub 2016/05/04. https://doi.org/10.1200/jco.2015.64.8931 PMID: 27138582.
41. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. 2016; 7:10582. https://doi.org/10.1038/ncomms10582 PMID: 26822383.